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Abstract
Introduction Acetaminophen (APAP) toxicity is the most
common cause of acute liver failure in the US and Europe.
Massive hepatocyte necrosis is the predominant feature of
APAP-induced acute liver injury (ALI). Liver regeneration is a vital
process for survival after a toxic insult, it occurs at a relative late
time point after the injurious phase. Currently, N-acetylcysteine
(NAC), a glutathione precursor, is the antidote for
acetaminophen overdose. However, NAC is effective only for
patients who present within hours of an acute overdose, and is
less effective for late-presenting patients. It is possible that in
delayed patients, previously reduced endogenous glutathione
(GSH) level has restored and prolonged treatment with NAC
might be toxic and impair liver regeneration. Therefore, we
hypothesize that prolonged treatment with NAC impairs liver
regeneration in ALI induced by APAP.
Methods ALI was induced in C57BL/6 male mice by a single
dose of APAP (350 mg/kg) by intraperitoneal injection. After two
hours of APAP challenge, the mice were given 100 mg/kg NAC
dissolved in 0.6 mL saline, or saline treatment every 12 hours for
a total of 72 hours.
Results Seventy-two hours after APAP challenge, compared
with saline treatment, NAC treatment significantly increased
serum transaminases (alanine transaminase/aspartate
aminotransferase), induced evident hepatocyte vacuolation in
the periportal area and delayed liver regeneration seen in
histopathology. This detrimental effect was associated with
reduced hepatic nuclear factor (NF)-κB DNA binding and
decreased expression of cell cycle protein cyclin D1, two
important factors in liver regeneration.
Conclusions Prolonged treatment with NAC impairs liver
regeneration in ALI induced by APAP.
Introduction
Acetaminophen (APAP) toxicity is the most common cause of
acute liver failure in the US and Europe [1]; however, the
underlying mechanisms of APAP-induced hepatotoxicity are
still not completely understood. The toxic response to APAP is
triggered by a highly reactive metabolite, N-acetyl-p-benzoqui-
none imine (NAPQI), which reacts with and depletes glutath-
ione (GSH), after which it forms covalent adducts and initiates
mitochondrial oxidative stress [2,3]. This increases the mem-
brane permeability transition and causes the collapse of the
mitochondrial membrane potential, which results in a dimin-
ished mitochondrial capacity to synthesize ATP [4], and ATP
depletion leads to cell death. Massive necrosis of the hepato-
cyte is a characteristic feature of APAP-induced acute lung
injury (ALI) [5].
Liver regeneration is a vital process for survival after a toxic
insult [6,7]. Regeneration ensures the replacement of necrotic
cells and the full recovery of organ function. As hepatocytes
are mostly in a quiescent state (G0), the regeneration process
requires entry into the highly regulated cell cycle [8]. The
induction of cyclin D1 is the most reliable marker for cell cycle
(G1 phase) progression in hepatocytes. Once hepatocytes
express cyclin D1, they have passed the G1 restriction point
and are committed to DNA replication [8].Page 1 of 7
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nuclear factor (NF)-κB is thought to play a major role in the ini-
tiation of liver regeneration after cell or tissue loss (such as by
hepatotectomy) [8]. In addition, nutrients and metabolic status
can also influence regeneration, because APAP induces mas-
sive hepatocyte necrosis. After the loss of a large number of
parenchymal cells, the metabolic work of surviving hepato-
cytes is increased and more ATP is needed for maintaining
homeostasis and regeneration [8].
Currently, N-acetylcysteine (NAC), a GSH precursor, is the
antidote for APAP overdose [9]. However, this antidotal ther-
apy is effective only for patients who present within hours of an
acute overdose, and is less effective for late-presenting
patients [9,10]. There are two possibilities: delayed treatment
with NAC is not effective when massive hepatonecrosis has
occurred; at a late hour, liver regeneration becomes evident
and plays a crucial role in liver recovery; however, delayed
NAC treatment does not maintain the proliferation of primary
hepatocytes [11]. In addition, there is evidence showing that
reduced endogenous GSH concentration gradually gets back
to a normal level at the late time point [12], after which contin-
uous treatment with NAC may no longer replenish endog-
enous GSH. Instead, it might interfere with glucose
metabolism, because NAC is involved in glucose and mito-
chondrial tricarboxylic acid (TCA) metabolisms [13]; and a
high dose of NAC (600 to 1200 mg/kg) impairs liver glucose
metabolism [13]. The liver is responsible for the metabolism of
carbohydrate, lipid and protein; these processes are all inter-
linked [14], therefore, prolonged treatment with a high dose of
NAC may interfere with hepatic normal metabolic functions
and impairs liver recovery from APAP hepatotoxicity.
At present, NAC is also used to treat non-acetaminophen-
induced hepatotoxicity [15,16]. However, there are limited
data available on the efficacy and safety of NAC. The doses
vary from 100 mg/kg/20 hours to 300 mg/kg/24 hours in
patients; the median duration of NAC administration in chil-
dren with non-APAP-induced ALI is five days (range = 1 to 77
days) [16]. In an amatoxin (a toxic peptide from poisoning
mushroom) induced hepatotoxicity model, NAC was adminis-
tered at a dosage of 1200 mg/kg and repeated every four
hours at a dosage of 600 mg/kg for a total of 48 hours. The
NAC-treated mice have higher serum alanine transaminase
(ALT)/aspartate aminotransferase (AST) than the amatoxin-
challenged mice treated with saline [15], this indicates that
prolonged treatment with a high dose of NAC might be toxic.
Based on this information, we hypothesized that NAC might
impair liver regeneration in ALI induced by APAP. To evaluate
this idea, ALI was induced in mice by APAP intraperitoneal
injection, and the mice were observed over a 72-hour period.
Compared with saline treatment, prolonged treatment with
NAC increased serum ALT/AST and also induced evident
hepatocyte vacuolation and delayed liver regeneration as
shown by histopathology; This detrimental effect was associ-
ated with reduced hepatic NF-κB DNA binding and decreased
expression of cell cycle protein cyclin D1, two important fac-
tors in liver regeneration. In conclusion, prolonged treatment
with therapeutic dose of NAC impairs liver regeneration in ALI
induced by APAP, reevaluation of optimal doses and duration
of NAC therapy is needed.
Materials and methods
Materials
All chemicals were purchased from Sigma-Aldrich Chemical
Co. (St. Louis, MO, USA) unless otherwise noted.
Animal model and experimental groups
This research protocol complied with the regulations regard-
ing the care and use of experimental animals published by the
National Institutes of Health and was approved by the Institu-
tional Animal Use and Care Committee of the University of
Pittsburgh Medical School. Male C57BL/6 mice weighing 20
to 25 g (Jackson Laboratories, Bar Harbor, ME, USA) were
used in this study. The animals were maintained at the Univer-
sity of Pittsburgh Animal Research Center with a 12-hour light-
dark cycle and free access to standard laboratory food and
water. The animals were fasted over night prior to the experi-
ments.
Experiment A
ALI was induced by a single dose of APAP (350 mg/kg dis-
solved in 1 mL sterile saline) administered by intraperitoneal
injection. APAP-challenged mice were then randomized into
the NAC (n = 7) group or the saline group (n = 7). Six mice
injected with saline not containing APAP served as a control
group. Two hours after APAP administration, each group was
given the following treatments every 12 hours for a total of 72
hours: 100 mg/kg NAC dissolved in 0.6 mL sterile saline for
the NAC group, and 0.6 mL saline for the saline group and the
control group. Seventy-two hours after APAP injection, all sur-
viving mice in each group were anaesthetized with sodium
pentobarbital (90 mg/kg intraperitoneally), and the following
procedures were performed: blood was aspirated from the
heart for the subsequent measurements of ALT and AST; the
left lobe of the liver was harvested for pathology (H&E stain-
ing); and the right lobe of the liver was harvested and frozen
for measurement of hepatic NF-κB DNA binding by electro-
phoretic mobility shift assays (EMSA) and hepatic tissue cyclin
D1 expression by western blot.
Experiment B
Three separate groups of mice were treated as described
above with the exception that the treatment period was only
24 hours (n = 6 for each group).Page 2 of 7
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Plasma levels of AST and ALT were measured at 37°C with a
commercially available kit (Sigma Diagnostic, St Louis, MO,
USA).
Histological analysis
Consecutive sections (5 μm) of paraffin-embedded liver were
prepared for H&E staining. The percentage of necrosis was
estimated by evaluating the number of microscopic fields with
necrosis compared with the entire cross-section. In general,
necrosis was estimated at low power (×100) and questiona-
ble areas were evaluated at higher magnification (×200 or
×400). The pathologist (XH) evaluated all histological sections
in a blinded fashion. Inflammatory cell infiltration results were
scored semi-quantitatively by averaging the number of inflam-
matory cells per microscopic field at a magnification of 200×.
Five fields were evaluated per tissue sample, and six animals
in each group were examined.
Tissue myeloperoxidase
Neutrophil infiltration was measured at 72 hours by determin-
ing myeloperoxidase (MPO) activity in liver tissue homoge-
nates and was used as an index of neutrophil infiltration in all
groups. At the time of sample determination, liver tissue sam-
ples (400 mg) were harvested and snap frozen immediately in
liquid nitrogen and stored at -70°C until analysis was per-
formed. Samples were homogenized in suspension buffer (50
mmol/L potassium phosphate/0.5% hexadecyltrimethylammo-
nium bromide; pH 6.0), sonicated on ice, freeze-thawed twice,
resonicated and then centrifuged for 15 minutes as 20,000 g
at 4°C. Liver supernatants were heated for two hours at 60°C,
and recentrifuged for 15 minutes at 20,000 g at 4°C.
To determine the MPO activity, 100 μL of the supernatants
was incubated for three minutes at 37°C in a reaction solution
containing 40% PBS, 8% N,N-dimethylformamide, 1.6 mmol/
L 3,3', 5,5'-tetramethylbenzidine, 0.3 mmol/L hydrogen perox-
ide and 80 mmol/L sodium phosphate (pH 5.4). The reaction
was stopped by adding ice-cold 800 mmol/L acetic acid solu-
tion (pH 3.0) and by placing the assay tubes on ice. Samples
were read at 655 nm and total MPO activity calculated as the
change in absorbency per minute per gram of tissue multiplied
by the dilution factor. The levels were expressed as units per
gram of tissue (U/g) [17].
EMSA
NF-κB activation was determined by EMSA as previously
described [18]. The gels were dried and exposed to Biomax
film (Kodak, Rochester, NY, USA) at -70°C overnight with use
of an intensifying screen.
Western blot
Liver protein was extracted as previously described [19].
Equivalent amounts of protein were boiled in sample buffer
and separated on 7.5% pre-cast SDS-PAGE (Bio-Rad, Her-
cules, CA, USA) and transferred to nylon membranes. Mem-
branes were then probed with a specific antibody against
cyclin D1 (Cell signaling Technology, Lexington, KY, USA)
protein, visualized with an Enhanced Chemiluminescence sub-
strate (ECL, Amersham Pharmacia Biotech, Piscataway, NJ,
USA) and exposed to x-ray film according to the manufac-
turer's instructions.
Statistical methods
Results are presented as means ± standard error of the mean
(SEM). Continuous data were analyzed using student's t-test
or analysis of variance followed by Fisher's least significant dif-
ference test. P values less than 0.05 were considered signifi-
cant. Summary statistics are presented for densitometry
results from studies using western blot for cyclin D1 expres-
sion but these results were not subjected to statistical analysis
because the method employed was only semi-quantitative (n
= 6).
Results
Prolonged treatment with NAC increases serum ALT/
AST at 72-hour time point
Twenty-four hours after APAP injection, compared with saline
treatment, NAC therapy significantly decreased serum con-
centrations of ALT/AST (Figure 1a, b). However, 72 hours
after APAP challenge, compared with saline treatment, NAC
therapy significantly increased serum ALT/AST concentra-
tions (Figure 1c, d).
Prolonged treatment with NAC impairs liver 
regeneration in histopathology
In histological evaluation 72 hours after ALI induction, com-
pared with control animals, saline-treated mice demonstrated
a small number of scattered necrotic hepatocytes, evident
regeneration and extensive infiltration of inflammatory cells
(240 ± 40 per high power field, n = 6) in the centrilobular
region. In contrast, NAC-treated mice demonstrated 10%
necrotic hepatocytes and extensive inflammatory cell infiltra-
tion (250 ± 35 per high power field, n = 6) in the centrilobular
region; however, no evident regeneration was seen (Figure 2;
arrows indicate periportal areas shown in Figure 3). In addi-
tion, prolonged treatment with NAC also induced evident
hepatocyte vacuolation in the periportal area (Figure 3).
Prolonged treatment with NAC increases hepatic tissue 
MPO level
Tissue MPO activity was determined as an index of neutrophil
infiltration after the APAP injection in the liver. Liver MPO activ-
ity values for the control group were 4.2 ± 0.29 U/g (Figure 4).
Seventy-two hours after ALI, these values increased to 5.88 ±
1.19 U/g in the saline group. The liver MPO activity was signif-
icantly increased in the NAC therapy group, to a value of 9.5
± 0.70 U/g (P < 0.05), when compared with the saline group
(n = six for each group, data were shown as mean ± SEM).Page 3 of 7
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NF-κB is a pleiotropic transcription factor whose activation
has been linked to inflammatory and destructive processes, as
well as initiation of regenerative programs in the injured liver.
Blockade of HMGB1 protects against ischemia-reperfusion (I/
R)-induced liver injury; this protection is associated with
increased NF-κB DNA binding activity [20]. Enhanced NF-κB
activation is seen in mice that are protected from hepatic I/R
following blockade of the HMGB1 receptor for advanced gly-
cation end products [21]. Therefore, we examined the impact
of APAP on activation of NF-κB 72 hours after APAP injection
and tested the effect of NAC treatment. There was a low basal
level of NF-κB DNA binding in the hepatic tissue samples in
the control group. In the saline group, there was a marked
increase in NF-κB DNA binding. Prolonged treatment of mice
after APAP challenge with NAC clearly decreased NF-κB
DNA binding relative to the degree observed in mice treated
with saline (Figure 5).
Prolonged treatment with NAC decreases hepatic cyclin 
D1 expression
The timely onset of tissue repair processes can limit liver injury
and promote regeneration of lost tissue mass [7]. The induc-
tion of cyclin D1 is the most reliable marker for cell cycle (G1
phase) progression in hepatocytes [8]. Western blot was per-
formed using whole-cell extracts prepared from liver tissue to
assess expression of cyclin D1 in mice subjected to ALI or the
control procedure. Cyclin D1 expression in the control group
and the NAC group was minimal (Figure 6). In contrast, cyclin
D1 expression was clearly observed in saline-treated animals
at 72 hours after APAP administration, which indicates that
Figure 1
Effect of treatment with NAC or saline on serum ALT/AST in an APAP-induced ALI modelit   r saline on serum ALT/AST in an APAP-induced ALI model. (a, b) Acute liver injury (ALI) was induced in C57Bl/6 male 
mice with a single dose of acetaminophen (APAP) (350 mg/kg) by intraperitoneal injection. Two hours after APAP injection, the animals were treated 
with 100 mg/kg N-acetyl-cysteine (NAC) dissolved in 0.6 mL saline or 0.6 mL saline every 12 hours. Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were measured 24 hours after APAP injection (n = 6 surviving mice for each group). Results are means ± standard error of 
the mean (SEM). * P < 0.05 versus control; † P < 0.05 vs. the NAC group. (c, d) Three separate groups of mice were used. ALI was induced as 
described above. Two hours after APAP challenge, the animals were given the same treatment every 12 hours for a total of 72 hours. ALT and AST 
were measured 72 hours after APAP injection (n = 6 to 7 surviving mice for each group). Results are means ± SEM. * P < 0.05 vs. control; † P < 
0.05 vs. the NAC group.Page 4 of 7
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Discussion
The purpose of this study was to test the hypothesis that pro-
longed treatment with NAC impairs liver regeneration in ALI
induced by APAP. The major and the novel findings of this
investigation are: prolonged treatment with NAC increases
serum ALT/AST and delays liver regeneration 72 hours after
APAP administration; prolonged treatment with a therapeutic
dose of NAC induces evident hepatocyte vacuolation around
periportal area; the detrimental effect is associated with
reduced NF-κB DNA binding; and prolonged NAC therapy
significantly decreases the expression of cell cycle protein
cyclin D1 in liver tissue.
In this study, prolonged NAC treatment demonstrated a large
amount of hepatonecrosis in the centrilobular region and evi-
dent hepatocyte vacuolation in the periportal area; and also
induced increased neutrophil infiltration as determined by
measuring myeloperoxidase activity in total liver extracts. In
addition, no evident regeneration was seen in the NAC group
by histopathology. In contrast, saline treatment showed only a
small number of scattered necrotic hepatocytes and evident
Figure 2
Effect of treatment with NAC or saline on pathology in mice with ALIli   t l  i  ice ith ALI. H&E staining was assessed 72 hour after induction of acute liver injury (ALI) or 
sham procedure (n = 6 for each group). Typical picture is shown. Arrows indicate periportal areas shown in Figure 3. NAC = N-acetyl-cysteine.
Figure 3
Prolonged treatment with NAC induces periportal hepatocytes vacuolation in mice with ALI. H&E staining was assessed 72 hour after induction of 
acute liver injury (ALI) or sham procedure (n = 6 for each group). Typical picture is shown. NAC = N-acetyl-cysteine.Page 5 of 7
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delayed by prolonged NAC therapy and support the notion
that timely onset of tissue repair processes can limit liver injury
[7].
To elucidate the molecular basis of liver recovery in prolonged
NAC therapy, we investigated its effect on the NF-κB signaling
pathway because activation of NF-κB is linked strongly not
only to the inflammatory response [20], but also to liver regen-
eration [8]. In addition, NF-κB is currently thought to play a
major role in the initiation of liver regeneration after cell or tis-
sue loss (such as partial hepatectomy) [8,22]. NF-κB activa-
tion also induces increased expression of survival genes,
including BCLXL and A1 [23]. Our data suggested that pro-
longed treatment with NAC is associated with a detrimental
effect characterized by reduced NF-κB DNA binding.
Although NF-κB activation modulates inflammation [24], it is
also known to protect hepatocytes from cell death, and inhibi-
tion of NF-κB after partial hepatectomy results in massive
hepatocyte apoptosis, worsens liver injury and decreases sur-
vival [25]. Enhanced NF-κB activation is also seen in mice that
are protected from hepatic I/R following blockade of the
receptor for advanced glycation end products [21]. There is
evidence suggesting that the impact of APAP toxicity ensues,
at least in part, by dramatic modulation of inflammatory and/or
regeneration programs [26]. After massive hepatonecrosis
induced by APAP overdose, liver regeneration is a vital proc-
ess for survival after a toxic insult [6,7], and NF-κB activation
plays an important role in liver regeneration [8]. Prolonged
treatment with NAC impairs liver regeneration, at least partly
by inhibiting the NF-κB activation pathway.
Massive hepatocyte necrosis is the predominant feature of
APAP-induced ALI. Tissue repair is an important determinant
of final outcome of toxicant-induced injury [7], and cyclin D1 is
an important cell cycle protein. In the current investigation, our
western blot data showed that prolonged NAC treatment
markedly decreased the level of cyclin D1 expression in the
APAP-challenged liver tissue. The change in cyclin D1 expres-
sion was associated with increased serum ALT/AST and
delayed liver regeneration in NAC-treated mice receiving
APAP, suggesting that prolonged NAC therapy likely inhibits
cyclin D1-mediated regeneration pathway, and the reduced
cyclin D1 expression might be modulated by decreased NF-
κB DNA binding [8].
Figure 4
Effect of treatment with NAC or saline on hepatic MPO activity in mice with ALI
with ALI. Liver myeloperoxidase (MPO) was assessed 72 hours after 
induction of acute liver injury (ALI) or sham procedure. Results are 
means ± standard error of the mean (SEM). * P < 0.05 versus control; 
† P < 0.05 vs. saline. NAC = N-acetyl-cysteine.
Figure 5
Effect of treatment with NAC or saline on NF-κB DNA binding in nuclear extr cts prepared from hepatic tissue samples from mice with ALI
nuclear extracts prepared from hepatic tissue samples from mice with 
ALI. Nuclear factor (NF) κB DNA binding was assessed 72 hours after 
induction of acute liver injury (ALI) or sham procedure. The figure 
depicts results from five representative assays. Typical gels are 
depicted. NAC = N-acetyl-cysteine.
Figure 6
Effect of treatment with NAC or saline on the expression of cyclin D1 in the hepa ic tissue
the hepatic tissue. Western blot was performed using hepatic extracts 
prepared from tissues obtained 72 hours after acetaminophen injec-
tion. The figure depicts results from five representative assays. Typical 
gels are depicted. NAC = N-acetyl-cysteine.Page 6 of 7
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Prolonged treatment with NAC impairs liver regeneration in
ALI induced by APAP, reevaluation of optimal doses and dura-
tion of NAC therapy is needed.
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Key messages
• Prolonged treatment with NAC increases serum ALT/
AST in APAP-challenged mice.
• Prolonged treatment with NAC induces hepatocyte vac-
uolation in APAP-challenged mice.
• Prolonged treatment with NAC delays hepatocyte 
regeneration in APAP-challenged mice.
• Prolonged treatment with NAC delays liver recovery 
from APAP hepatotoxicity, reevaluation of optimal doses 
and duration of NAC therapy is needed.Page 7 of 7
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